Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds ...

Investor David Lazar has come to the rescue of cash-strapped Cyclacel Pharmaceuticals, pumping $3 million into the biotech as ...

After being acquired by clinical-stage ADC company Oqory, Vincerx ended 2024 with a workforce reduction and C-suite clear-out ...

Will 2025 be better? After another tough year, the answer to that question will shape the prospects of innumerable drug ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Last December, the FDA published its final guidance on predetermined change control plans, or PCCPs, with recommendations to ...

The festive season may be a chance to rest up and recharge—but tell that to biotech dealmakers, who have been as busy as ever ...

Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for ...

Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new ...

Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of ...

In September of last year, the FDA said it had begun exploring the potential health effects of various metals that have been ...